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Exposure on cell surface and extensive arginine methylation of
ewing sarcoma (EWS) protein
Abstract
In contrast to the knowledge regarding the function of chimeric Ewing sarcoma (EWS) fusion proteins
that arise from chromosomal translocation, the cellular function of the RNA binding EWS protein is
poorly characterized. EWS protein had been found mainly in the nucleus. In this report we show that
EWS protein is not only found in the nucleus and cytosol but also on cell surfaces. After cell-surface
biotinylation, isoelectric focusing of membrane fraction, avidin-agarose extraction of biotinylated
proteins, and SDS-polyacrylamide gel electrophoresis, EWS protein was identified by matrix-assisted
laser desorption ionization and nanoelectrospray tandem mass spectrometry of in-gel-digested peptides.
These analyses revealed that the protein, having repeated RGG motifs, is extensively asymmetrically
dimethylated on arginine residues, the sites of which have been mapped by mass spectrometric methods.
Out of a total of 30 Arg-Gly sequences, 29 arginines were found to be at least partially methylated. The
Arg-Gly-Gly sequence was present in 21 of the 29 methylation sites, and in contrast to other methylated
proteins, only 11 (38%) methylated arginine residues were found in the Gly-Arg-Gly sequence. The
presence of Gly on the C-terminal side of the arginine residue seems to be a prerequisite for recognition
by a protein-arginine N-methyltransferase (PRMT) catalyzing this asymmetric dimethylation reaction.
One monomethylarginine and no symmetrically methylated arginine residue was found. The present
findings imply that RNA-binding EWS protein shuttles from the nucleus to the cell surface in a
methylated form, the role of which is discussed.
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In contrast to the knowledge regarding the function of
chimeric Ewing sarcoma (EWS) fusion proteins that
arise from chromosomal translocation, the cellular func-
tion of the RNA binding EWS protein is poorly charac-
terized. EWS protein had been found mainly in the nu-
cleus. In this report we show that EWS protein is not
only found in the nucleus and cytosol but also on cell
surfaces. After cell-surface biotinylation, isoelectric fo-
cusing of membrane fraction, avidin-agarose extraction
of biotinylated proteins, and SDS-polyacrylamide gel
electrophoresis, EWS protein was identified by matrix-
assisted laser desorption ionization and nanoelectro-
spray tandem mass spectrometry of in-gel-digested pep-
tides. These analyses revealed that the protein, having
repeated RGG motifs, is extensively asymmetrically
dimethylated on arginine residues, the sites of which
have been mapped by mass spectrometric methods. Out of a
total of 30 Arg-Gly sequences, 29 arginines were found to be
at least partially methylated. The Arg-Gly-Gly sequence
was present in 21 of the 29 methylation sites, and in con-
trast to other methylated proteins, only 11 (38%) methyl-
ated arginine residues were found in the Gly-Arg-Gly se-
quence. The presence of Gly on the C-terminal side of the
arginine residue seems to be a prerequisite for recognition
by a protein-arginine N-methyltransferase (PRMT) cata-
lyzing this asymmetric dimethylation reaction. One
monomethylarginine and no symmetrically methylated ar-
ginine residue was found. The present findings imply that
RNA-binding EWS protein shuttles from the nucleus to the
cell surface in a methylated form, the role of which is
discussed.
While investigating a 90-kDa anti-cyclophilin (anti-CyP)1
immunoreactive band we noticed that anti-CyP antibodies rec-
ognized the RNA-binding Ewing sarcoma (EWS) protein and
not a cyclophilin. The EWS gene is involved in tumor-related
chromosomal translocations that associate part of EWS gene
with various genes encoding transcription factors (1). The N-
terminal transcriptional activation domain of EWS is fused to
C-terminal DNA binding domains of corresponding partners.
The translocation produces chimeric EWS proteins with trans-
forming potential (2–7). The EWS gene of Ewing sarcoma and
primitive neuroectodermal tumor is translocated to one of dif-
ferent members of the ETS (erythroblastosis virus-transform-
ing sequence) family that contains the highly conserved DNA
binding ETS domain. Often the ETS domain is derived from
FLI-1 (Friend leukemia integration-1) and in rare cases from
ERG (ETS-related gene), ETV-1 (ETS translocation variant-1),
E1AF (E1A factor), or FEV (fifth Ewing variant). In malignant
melanoma of soft parts, EWS is fused to ATF-1, in intra-
abdominal desmoplasmic small round-cell tumor to WT-1, in
myxoid liposarcoma to CHOP, and in myxoid chrondrosarcoma
to CHN (8).
The cellular role of wild-type EWS protein remains less clear.
The EWS protein is a nuclear protein with unknown function
containing a C-terminal RNA binding motif and a N-terminal
activation domain (9–11). The IQ domain of the EWS protein is
involved in calmodulin binding and protein kinase C phospho-
rylation (12). EWS protein interacts with an SH3 domain of
Bruton’s tyrosine kinase and has been identified in B cells as a
phosphotyrosine-containing protein (13). G-coupled receptor
signaling and other stimuli of tyrosine kinase Pyk2 block the
interaction between EWS protein and Pyk2. Partitioning of the
EWS protein into a ribosome-associated fraction indicated that
the role for EWS in gene expression includes an extranuclear
action (14).
In the present investigation we show the EWS protein is not
only localized in the nucleus and cytosol but also on the surface
of cells and that it is posttranslationally methylated at arginine
residues. The identified v-NG,NG-dimethylarginine residues of
EWS protein let us modify a previously reported consensus
sequence for asymmetric dimethylarginine formation in
proteins.
EXPERIMENTAL PROCEDURES
Materials—Stock cultures of Jurkat cells, a tumor T lymphoma cell
line, were kindly provided by Dr. J. Kemler-Carraneo (Abteilung Kli-
nische Immunologie, Universita¨tsspital Zu¨rich). Peripheral blood
mononuclear (PBM) cells and human cutaneous T lymphoma cell line
(H9) were obtained from the National Center for Retroviruses (Univer-
sity of Zu¨rich). Purified polyclonal antibodies raised against human
CyPA and CyPB (anti-CyP) were kindly provided by G. Woerly
(Toxikologisches Institut der Universita¨t Zu¨rich, Schwerzenbach). Poly-
clonal antibody 677 against the N terminus of EWS protein (anti-EWS)
was a generous gift from Dr. Olivier Delattre (Institut Curie, Pathologie
Mole´culaire des Cancers, Paris Cedex).
Cell Cultures—Human Jurkat cells were grown in RPMI 1640 me-
dium (Sigma) supplemented with 5% newborn calf serum (Life Tech-
nologies), 15 mM HEPES, 2 mM L-glutamine, 50 mM b-mercaptoethanol,
and 1% (w/v) penicillin and streptomycin (Life Technologies) in a hu-
midified 5% CO2 atmosphere at 37 °C. PBM cells were isolated by
Ficoll-Hypaque gradient centrifugation. The cells were washed with
phosphate-buffered saline, pH 7.4 (PBS), and stimulated with 2 mg/ml
phytohemagglutinin in RPMI 1640 medium supplemented with 20%
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fetal calf serum (Life Technologies), 15 mM HEPES, 2 mM L-glutamine,
50 mM b-mercaptoethanol, and 1% (w/v) penicillin and streptomycin in
a humidified 5% CO2 atmosphere at 37 °C. Human H9 cell line was
grown in RPMI 1640 medium supplemented with 20% fetal calf serum,
15 mM HEPES, 2 mM L-glutamine, 50 mM b-mercaptoethanol, and 1%
(w/v) penicillin and streptomycin in a humidified 5% CO2 atmosphere at
37 °C.
Biotinylation of Cell Surface Proteins—Cell-surface biotinylation was
performed as described (15) with some modification. 2 3 108 cells were
washed three times with ice-cold PBS, suspended in PBS (25 3 106
cells/ml), and incubated with 0.5 mg/ml sulfosuccinimidobiotin (Calbio-
chem) for 1 h at 4 °C. The biotinylation procedure was stopped by
replacing the labeling solution with culture medium. After incubation
for 10 min at 4 °C, cells were washed twice with PBS.
Biotinylated or non-labeled cells were solubilized (25 3 106 cells/ml)
in lysis buffer containing 1% (w/v) Triton X-100, PBS, protease inhibitor
mixture (20 mg/ml pancreas extract, 5 mg/ml Pronase, 0.5 mg/ml ther-
molysin, 3 mg/ml chymotrypsin, 330 mg/ml papain; Roche Molecular
Biochemicals), 2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5
mM dithiothreitol for 40 min on ice with occasional vortexing. The cell
lysates were centrifuged at 480 3 g for 5 min followed by 15000 3 g for
15 min. Obtained supernatants were then subjected to isoelectric focus-
ing followed by avidin-agarose extraction or directly to avidin-agarose
extraction and immunoprecipitation experiments. The Bio-Rad protein
assay kit was used to determine protein concentrations.
Isolation of Membrane-enriched Fractions—All steps were performed
at 4 °C. Biotinylated or nonlabeled cells were harvested and washed
three times with ice-cold PBS. Pelleted cells were suspended (5 3 108
cells/ml) in homogenizing buffer containing 25 mM Tris-HCl, pH 7.6,
10% (v/v) glycerol, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 2 mM EDTA, and protease inhibitor mixture. Cells were ho-
mogenized with a Dounce homogenizer (20 strokes), and the suspension
was centrifuged at 500 3 g. The supernatant was then centrifuged for
10 min at 15,000 3 g, and a membrane pellet obtained at 150000 3 g for
1 h was used for further purification. This supernatant was designated
as cytosolic fraction. Pellets were solubilized in 8 M urea, 2% (w/v)
CHAPS, 15 mM dithiothreitol, 2% (v/v) Bio-Lyte ampholytes (Bio-Rad),
pH 3–10, for 40 min at room temperature. Insoluble material was
removed by centrifugation at 10,000 3 g for 15 min, and the superna-
tant was designated as membrane fraction.
Isoelectric Focusing—Isoelectric focusing using a Mini Rotofor cell
(Bio-Rad) was done as recommended by the supplier. After cell-surface
biotinylation, part of the detergent lysates (17 mg) or solubilized mem-
brane fraction (15 mg) were added to the Rotophor cell containing 13 ml
of 8 M urea, 2% (w/v) CHAPS, 15 mM dithiothreitol, 2% (v/v) Bio-Lyte
ampholytes, pH 3–10, after prefocusing for 1 h at 12 W. Focusing was
carried out at 12 W for 5 h at 10 °C. The 20 fractions were harvested,
and their pH values were measured. After Western blot analysis, the
fractions of interest were pooled and concentrated with Centricon
(YM-30; Millipore), and biotinylated proteins were extracted with
avidin-agarose.
Avidin-Agarose Extraction—Either the detergent lysate or mem-
brane fraction pooled after isoelectric focusing was incubated with
avidin-agarose (Sigma) overnight on a rotary device at 4 °C. The affinity
gel was then washed 3 times with 1% (w/v) Triton X-100, 0.2% (w/v)
SDS, 5 mM EDTA in PBS followed by a wash without SDS and one with
water. The captured biotinylated proteins were eluted from the agarose
with reducing 2-fold Laemmli buffer heated for 5 min at 95 °C.
In-gel Digestion and Mass Spectrometry—Proteins were separated by
SDS-PAGE (7.5%, 0.75 mm thickness) and stained with 0.2% (w/v)
Coomassie Brilliant Blue R250 in 50% (v/v) ethanol and 10% (v/v) acetic
acid for 30 min. Protein bands of interest were excised from the gel and
in-gel-digested with trypsin (Promega) or chymotrypsin (Roche Molec-
ular Biochemicals) following the procedure of Shevchenko et al. (16).
Upon reduction of the disulfide bonds of the protein with tris(2-carboxy-
ethylphosphine) hydrochloride (Pierce), cysteines were alkylated with
iodoacetamide (Sigma). Digestions with trypsin (400 ng) were carried
out overnight at 37 °C in 100 mM ammonium bicarbonate buffer, pH 8.3,
and 4 mM calcium chloride. Digestions with chymotrypsin (500 ng) were
performed overnight at 25 °C in the same buffer, pH 8.0. The resulting
peptides were extracted from the gel pieces and desalted using pipette
tips with C18 resins (Millipore). Matrix-assisted laser desorption ioni-
zation time-of-flight (MALDI-TOF) mass spectra of the entire digests
were recorded on a Bruker Biflex instrument in the reflector mode
employing pulsed ion extraction. a-Cyano-4-hydroxycinnamic acid
(Fluka) was used as the matrix. The MALDI mass spectra were mass
calibrated using ion signals mainly from autoproteolytic fragments of
trypsin and chymotrypsin, respectively. Electrospray ionization mass
spectra (MS) and tandem mass spectra (MS/MS) were acquired on an
API III1 triple-quadrupole instrument (PE-Sciex, Ontario, Canada)
equipped with a nanoelectrospray ion source (Protana, Odense,
Denmark).
Immunoprecipitation—The detergent lysates of cells were preincu-
bated with protein A-Sepharose (Amersham Pharmacia Biotech) for 2 h.
Anti-CyP antiserum or anti-EWS antiserum were added to the super-
natants, and the mixture was incubated at 4 °C for at least 12 h, and
then protein A-Sepharose was added for 2 h. The agarose pellet was
washed three times with 1% (w/v) Triton X-100, 2 mM EDTA, and 10 mM
Tris-HCl, pH 7.4, and the antigen was eluted from the gel with reducing
2-fold Laemmli buffer by heating for 5 min at 95 °C.
Western Blotting and Protein Detection by Enhanced Chemilumines-
cence—Proteins separated on 7.5% SDS-PAGE were transferred elec-
trophoretically to a nitrocellulose membrane (Schleicher and Schuell)
as described (17). After transfer, the membrane was blocked for 40 min
with 5% (w/v) milk powder dissolved in PBS and 0.25% (w/v) Tween 20
and incubated with the first antibodies anti-CyP or anti-EWS, respec-
tively, for 1 h at room temperature, followed by incubation with goat
anti-rabbit antibody coupled to horseradish peroxidase (Sigma) for 1 h
at room temperature. The detection was performed by enhanced chemi-
luminescence (ECL, Amersham Pharmacia Biotech).
RESULTS
Partial Purification of a 90-kDa Cell-surface Protein—Cell-
surface proteins of Jurkat and PBM cells were labeled under
physiological conditions with the impermeable biotinylation
reagent. Labeled surface proteins were extracted with avidin-
coupled agarose and separated by SDS-PAGE. Western blot
analysis with anti-CyP antibodies showed a strong signal of a
protein band with a molecular mass of about 90 kDa (Fig. 1A).
To obtain a pure protein in amounts high enough for identifi-
cation, a membrane fraction of Jurkat and PBM cells was
prepared by differential centrifugation after cell-surface biotin-
ylation. The solubilized proteins were further purified by iso-
electric focusing under denaturing conditions. The anti-CyP
immunoreactive protein was found in a pH range from 7.2 to
9.3. These fractions were pooled, and the biotinylated proteins
extracted with avidin-agarose and subjected to SDS-PAGE.
The Coomassie-stained band (Fig. 1B) containing the immuno-
reactive 90-kDa protein of interest (Fig. 1C) was clearly sepa-
rated from other proteins and was sufficiently pure to be sub-
jected for an identification procedure.
FIG. 1. Detection of a cell-surface anti-cyclophilin reactive
protein. PBM and Jurkat cells were biotinylated with sulfosuccinim-
idobiotin. Equal amounts of cell proteins (see “Experimental Proce-
dures”) were added to avidin-agarose gel, and biotinylated proteins
extracted. After elution with Laemmli buffer, aliquots were separated
on 7.5% SDS-PAGE, transferred to nitrocellulose, and analyzed by
Western blot using anti-CyP antibodies (A). The pellets of the mem-
brane fractions of Jurkat cells or PBM cells (PBMC) were solubilized
(see “Experimental Procedures”) and loaded for isoelectric focusing into
a Rotophor cell. After focusing, fractions containing the anti-CyP-im-
munoreactive protein were pooled, and biotinylated proteins were ex-
tracted with avidin-agarose, separated on 7.5% SDS-PAGE, and stained
with Coomassie Blue (B) or transferred and immunoblotted with anti-
CyP antibodies (C). The molecular masses of marker proteins are indi-
cated (in kDa).
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Identification of the 90-kDa Band—The 90-kDa Coomassie-
stained gel band containing the protein of interest was excised
and in-gel-digested with trypsin, and the resulting peptides
were analyzed by MALDI-MS (see “Experimental Procedures”).
A protein sequence data base search (Mascot Search) per-
formed with the obtained peptide masses (Table I) did not
provide an unequivocal result. RNA-binding protein EWS (1)
was retrieved with the highest score; however, some of the most
intense signals of the MALDI mass spectrum could not be
assigned to this protein. To confirm the identification of the
protein, nanoelectrospray MS/MS sequencing of selected pep-
tides was performed. Four MS/MS spectra were in complete
agreement with the predicted fragmentation pattern of pep-
tides 269–292, 411–424, 425–439, and 472–486 from RNA-
binding EWS protein and, thus, unambiguously verified the
identification of this protein (Fig. 2, Table I).
Assignment of Arginine Methylation Sites—The tandem
mass spectrum shown in Fig. 3 appeared to match peptide
615–632 from this protein, but the observed mass was 28 Da
higher than the mass calculated from the amino acid sequence.
Detailed analysis of the spectrum indicated that this peptide
most likely contains a dimethylated arginine residue located at
TABLE I
Summary of mass spectrometric data of proteolytic fragments from the in-gel-digested protein (see Fig. 1B)
Arginines found to be dimethylated in the corresponding peptides are in bold and underlined, and the only monomethylated arginine at position












2479.00 2479.04 QDHPSSMGVYGQESGGFSGPGENR 269–292 Assignment confirmed by MS/MS.
2055.07 2055.08 TGQPMIHIYLDKETGKPK 393–410
1449.62 1449.66 GDATVSYEDPPTAK 411–424 Assignment confirmed by MS/MS.
1683.70 1683.79 AAVEWFDGKDFQGSK 425–439 Assignment confirmed by MS/MS.
1692.88 1692.92 KKPPMNSMRGGLPPR 447–461
766.46 766.42 GMPPPLR 465–471 Cleavage at Arg-464, which is a potential
methylation site; Arg-471 is not
modified in this peptide.
1983.00 1982.99 GMPPPLRGGPGGPGGPGGPMGR 465–486 Cleavage at Arg-464 (potential
methylation site); dimethylation of
Arg-471 confirmed by MS/MS.
1968.99 1968.98 GMPPPLRGGPGGPGGPGGPMGR 465–486 Arg-471 is mono-methylated in this
peptide.
1206.53 1206.55 GGPGGPGGPGGPMGR 472–486 Cleavage at Arg-471 (potential
methylation site); assignment
confirmed by MS/MS.
3326.63 3326.72 MGGRGGDRGGFPPRGPRGSRGNPSGGGNVQHR 487–518
1380.69 1380.73 GGDRGGFPPRGPR 491–503 Cleavage at Arg-490 (potential
methylation site); Arg-503 was not
modified in this peptide.
2897.46 2897.50 GGDRGGFPPRGPRGSRGNPSGGGNVQHR 491–518
1506.66 1506.74 GSRGNPSGGGNVQHR 504–518 Cleavage at Arg-503, which is a potential
methylation site.
1777.83 1777.87 RGGPGGPPGPLMEQMGGR 615–632 Dimethylation of Arg-615 confirmed by
MS/MS.
896.55 896.54 RGGRGGPGK 633–641
Digestion with
chymotrypsin
3156.49 3156.47 GQQPAATAPTRPQDGNKPTETSQPQSSTGGY 128–158
1606.69 1606.72 GQQPPTSYPPQTGSY 233–247 Assignment confirmed by MS/MS.
1275.55 1275.56 RQDHPSSMGVY 268–278
1633.83 1633.81 SMSGPDNRGRGRGGF 293–307
1415.72 1415.75 SGPDNRGRGRGGF 295–307
1960.03 1959.99 SGPDNRGRGRGGFDRGGM 295–312
1187.59 1187.64 SRGGRGGGRGGM 313–324
3225.43 3225.39 NKPGGPMDEGPDLDLGPPVDPDEDSDNSAIY 334–364
1741.90 1741.98 RGGLPPREGRGMPPPL 455–470
1149.56 1149.54 RGGPGGPGGPGGPM 471–484 Arg-471 was not methylated in this
peptide.
1177.53 1177.57 RGGPGGPGGPGGPM 471–484 Arg-471 was dimethylated in this
peptide.
1971.07 1971.02 LPPPFPPPGGDRGRGGPGGM 552–571
727.43 727.45 RGGRGGL 572–578
858.50 858.49 RGGRGGLM 572–579
1760.93 1760.90 RGGRGGLMDRGGPGGMF 572–588
1051.47 1051.47 MDRGGPGGMF 579–588 Dimethylation of Arg-581 confirmed by
MS/MS.
920.45 920.43 DRGGPGGMF 580–588 Dimethylation of Arg-581 confirmed by
MS/MS.
1174.58 1174.64 RGGRGGDRGGF 589–599
1248.60 1248.66 RGGRGMDRGGF 600–610
1315.68 1315.72 GGGRRGGPGGPPGPL 611–625
1834.94 1834.90 GGGRRGGPGGPPGPLMEQM 611–629
988.55 988.55 RGGPGGPPGPL 615–625 Dimethylation of Arg-615 confirmed by
MS/MS.
1507.74 1507.74 RGGPGGPPGPLMEQM 615–629
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position 615 (Table I). Another MS/MS spectrum was found to
be consistent with peptide 465–486 containing a dimethylargi-
nine residue at position 471.
Re-examination of the MALDI mass spectrum of the tryptic
digest revealed the presence of eight additional dimethylargi-
nines located in the C-terminal arginine- and glycine-rich do-
main of the protein (Fig. 2). Arginines 464, 471, 490, and 503
appear to be dimethylated to a large extent but not completely.
Trypsin does not cleave after methylated arginines (18, 19).
Analyses of tryptic peptides indicated cleavages at these four
arginines that were found to be modified in other peptides. In
addition, peptides containing the non-methylated arginines
471 and 503 were identified. A small fraction of arginine
471 (#15%) also occurs in the monomethylated form (Table I,
peptide 465–486).
To analyze the sites of arginine methylation more com-
FIG. 2. Amino acid sequence of the EWS protein. The C-terminal arginine- and glycine-rich domain of RNA-binding protein EWS contains
30 Arg-Gly sequences. Completely dimethylated arginine residues are in bold and underlined, and arginines found to be either dimethylated or
non-methylated are only in bold. Arginine 471 (shown in bold and in italics) is either dimethylated or non-methylated and also monomethylated
to a small extent. No proteolytic peptide containing arginine 330, which represents a potential site of arginine methylation, had been identified.
Regions of protein covered by peptide fragments from MS data (Table I) are highlighted.
FIG. 3. Tandem mass spectrum of the tryptic peptide 615–632 of EWS protein. Nanoelectrospray tandem mass spectrum of the triply
charged ion at m/z 593.5 corresponding to tryptic peptide RGGPGGPPGPLMEQMGGR (R, dimethylarginine). The singly and doubly charged
fragment ions are labeled according to the Roepstorff-Biemann nomenclature (38).
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pletely, RNA-binding protein EWS was in-gel-cleaved with chy-
motrypsin. MALDI-MS of the entire chymotryptic digest al-
lowed the identification of 19 additional dimethylarginines
(Table I and Fig. 2). Mainly peptides resulting from specific
cleavage after the known chymotryptic cleavage sites phen-
ylalanine, tyrosine, methionine, and leucine were assigned;
however, arginine 292 and 614 were also found to be suscepti-
ble to chymotryptic cleavage. Only uniquely assignable mass
peaks were reported. The identification of all peptides listed in
Table I was confirmed by the excellent agreement between the
observed molecular masses with those predicted from the
known sequences (within 0.006%). The assignment of three
dimethylarginine-containing peptides and of peptide 233–247
was ascertained by nanoelectrospray MS/MS analyses as noted
in Table I.
A qualitative amino acid analysis (data not shown) of an
EWS protein hydrolysate revealed the presence of asymmetric
dimethylarginine residues, whereas symmetric dimethylargi-
nine, if at all present, or monomethylarginine residues were
below the detection limit, although monomethylarginine is
present in small amounts according to the MS data. To check
the methylation state of EWS protein in the nucleus, the pro-
tein was isolated from the nucleus as described (12), in-gel
digested with either trypsin or chymotrypsin, and subjected to
MALDI-MS analysis (data not shown). The peptide map of
nuclear EWS protein was found to be comparable with the
peptide map of EWS protein isolated from the plasma mem-
brane, indicating a similar dimethylation pattern of arginine
residues of the nuclear EWS protein.
Cross-reactivity of EWS Protein with Anti-CyP Antibodies—
The detection of an immunoreactive band with anti-CyP anti-
bodies at the same position in SDS-PAGE as the EWS protein
indicated either cross-reactivity of the antibodies or cross-con-
tamination of the proteins. Thus immunoprecipitations with
anti-CyP antibodies and anti-EWS antibody were performed
from cell lysates followed by Western analysis with anti-CyP
antibodies (Fig. 4A) as well as with anti-EWS antibody (Fig.
4B). In any case a stronger signal was obtained in the Western
with anti-EWS antibody even if immunoprecipitation was done
with anti-CyP antibodies, indicating cross-reactivity of both
antibodies with EWS protein. No signals were observed if
(when) goat anti-rabbit antibody alone or rabbit antibodies
against several other proteins was used.
Excision of the immunoprecipitated 90-kDa Coomassie-
stained bands, in-gel digestion with trypsin, and MALDI-MS
analysis of tryptic peptides confirmed the presence of methyl-
ated RNA-binding protein EWS in anti-CyP and anti-EWS-
precipitated samples.
Occurrence of Cell Surface-localized EWS Protein in Different
Cell Lines—To ascertain that EWS protein is indeed present on
the cell surface, Jurkat, PBM, but also H9 cells were surface-
labeled with the impermeable biotinylation reagent, and bioti-
nylated proteins were extracted with avidin-coupled agarose.
The Western blot, now performed with anti-EWS antibody,
revealed the presence of EWS protein on all three cell types
(Fig. 5A). Densitometry showed an identical high content of
EWS protein on the surface of the tumor cell lines Jurkat and
H9, whereas in PBM cells the content of EWS protein was
drastically lower. On purifying the cell-surface biotinylated
proteins by isoelectric focusing of membrane-enriched fractions
as described in Fig. 1B, a strong signal was obtained again in
the Western blot analysis with anti-EWS antibody (Fig. 5B),
showing that EWS protein is indeed present on the cell surface.
To verify that the 90-kDa protein represents a surface-exposed
molecule and not an unspecifically extracted protein, proteins
from nonbiotinylated cells were extracted and analyzed by the
same procedure. Signals in the anti-CyP or anti-EWS Western
blot analysis were not found (not shown).
DISCUSSION
Our data show that the anti-CyP immunoreactive protein
located on the surface of T cells is not a cyclophilin but the EWS
protein. The anti-CyP antibodies cross-react with the EWS
protein as demonstrated by immunoprecipitation experiments.
The cause of the cross-reactivity is not obvious. Global align-
ment of the EWS protein sequence either with human CyPA or
CyPB using the program LALIGN revealed a low degree of
identity (8.8%) in both cases, and some of the identity seems to
be due to numerous glycines present in the proteins. The cross-
reactivity led us, however, to the finding that the EWS protein
is not only exposed on the cell surface of different cells but also
that its arginine residues are extensively and asymmetrically
FIG. 4. Cross-reactivity of EWS protein with anti-cyclophilin
antibodies. After preincubating the detergent lysates of Jurkat cells
with protein A-Sepharose, immunoprecipitation with the anti-CyP an-
tibodies (lane 1) or with the anti-EWS antibody (lane 2) was performed.
Immunoprecipitated proteins were subjected to Western blot analysis
using the anti-CyP antibodies (A) or the anti-EWS antibody (B). For
quantification of the bands, the ECL films were scanned, and intensi-
ties of the bands were calculated by using Multi-Analyst software
(Bio-Rad). The large band at 55 kDa (lanes 1 and 2) corresponds to the
heavy chain of the antibodies. Molecular mass standards (kDa) are
indicated.
FIG. 5. The presence and variation of EWS protein on cell
surfaces. Jurkat, H9, and PBM cells (PBMC) were biotinylated with
sulfosuccinimidobiotin. Equal amounts of cell proteins were extracted
as described in Fig. 1A. Aliquots were separated on 7.5% SDS-PAGE,
transferred to nitrocellulose, and analyzed by Western blot using anti-
EWS antibody (A). Samples obtained by cell surface biotinylation, mem-
brane fractionation, and isoelectric focusing followed by avidin-agarose
extraction (see Fig. 1B) were separated on 7.5% SDS-PAGE and sub-
jected to Western blot analysis with anti-EWS antibody (B). Molecular
mass standards (kDa) are indicated.
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dimethylated. These properties of the EWS protein shed a new
light on the functionality of this unusual multidomain protein.
The previously reported localization of EWS protein in the
nucleus (20) and the cytosol (14), both of which we confirmed
(data not shown), together with the present finding of the EWS
protein to be accessible on the cell surface means that this
protein shuttles between the nucleus, cytosol, and the cell
surface. A similar behavior was reported for nucleolin. This
major nucleolar protein shuttles between the cytosol and the
nucleus and has also been detected on the cell surface of dif-
ferent cells. The C-terminal domain of nucleolin is, as in the
EWS protein, rich in glycine residues and interspersed with
dimethylarginines. It was suggested as a potential receptor in
the human immunodeficiency virus binding processes by inter-
action with the V3 loop of gp120 (21). So far we found cell-
surface-exposed EWS protein in all investigated cells, i.e.
Jurkat, H9, C816645 T cell lines, and PBM cells, but also
NIH/3T3 fibroblasts (not shown). Remarkably, tumor cell lines
showed a higher level of EWS protein expression on the cell
surface (;4-fold) than PBM cells and fibroblasts.
Recognition Sequence of Asymmetric Methylation Sites—Ar-
ginine methylation is a post-translational modification found
mainly in nuclear proteins that interact with RNA (22). This
modification is catalyzed by protein-arginine N-methyltrans-
ferases (PRMTs), utilizing S-adenosyl-L-methionine as the
donor of methyl groups (23). Type I protein-arginine N-meth-
yltransferases (EC 2.1.1.23) catalyze the formation of NG-
monomethylarginine and asymmetric v-NG,NG-dimethylargi-
nine residues, whereas Type II enzymes catalyze the formation
of NG-monomethylarginine and symmetric v-NG,N9G-dimeth-
ylarginine residues (22). The Type III enzyme found in yeast
catalyzes the monomethylation of the internal d-guanidino ni-
trogen atom of arginine residues (24). Three Type I PRMTs
from mammalian cells PRMT1 (25), PRMT3 (26), and coactiva-
tor-associated arginine methyltransferase 1 (CARM1) (27)
have been reported. PRMT1, a predominantly nuclear protein,
methylates arginine residues of many proteins, among them
RNA-binding proteins (22, 28). PRMT3 is a predominantly
cytoplasmic protein whose activity overlaps with that of
PRMT1 (26). A number of in vivo substrates for Type I PRMTs
have been identified, including the heterogeneous nuclear ri-
bonucleoprotein A1 (29), fibrillarin, nucleolin (22), high molec-
ular weight fibroblast growth factor-2 (30), and poly(A)-binding
protein II (28).
The sites of methylated or dimethylated arginine residues
had been directly determined by Edman sequencing or by a
combination of Edman sequencing and mass spectrometric ap-
proaches. In this study, the arginine dimethylation sites of the
EWS protein from the cell surface of Jurkat and H9 cell lines
were elucidated by mass spectrometric peptide mapping and
sequencing. We found up to the present the EWS protein to be
the most extensively methylated protein in vivo in higher eu-
karyotes. From sequences of known sites of asymmetric argi-
nine methylation, a preferred recognition motif (G/F)-
GGRGG(G/F) had been proposed (Refs. 22 and 29; Table II).
The shorter sequence GRG had also been suggested as a spec-
ificity determinant for arginine methylation by a Type I en-
zyme, although the Gly at position 21 could be replaced by a
few amino acids other than glycine (31). Only the Gly 11
C-terminal of the arginine was found to be completely con-
served. In the present study, all 29 identified dimethylargin-
ines are indeed followed by a glycine (Table II). Conversely, all
arginines in Arg-Gly sequences mapped by mass spectrometry
(29 out of a total of 30 Arg-Gly sequences) were at least par-
tially methylated. The sequence Arg-Gly-Gly is present in 21 of
the 29 methylation sites; however, only 11 (38%) methylated
arginine residues were found in a Gly-Arg-Gly sequence. The
prevalence of Gly at positions 22 and 23 in EWS protein is
even higher than at position 21. Obvious deviations from the
suggested consensus sequence are the small number of pheny-
lalanines at position 23 and 13 and of glycines at position 13.
Thus, the suggested recognition sequence for asymmetric argi-
nine dimethylation is only partially consistent with the se-
quences identified in this study. Only the presence of the Gly
11 C-terminal of the arginine residue is a strict requirement
for asymmetric dimethylation but not the Gly N-terminal of the
arginine. The found differences may be attributed to an insuf-
ficiently defined consensus sequence based on only 20 in vivo
arginine methylation sites or to different Type I PRMTs with
similar specificity that are involved in methylation of the argi-
nine residues in EWS protein. Arginine methylation sites very
distinct from those found in EWS protein and the other sites
listed in Table II were observed in poly(A)-binding protein II. In
this protein, almost all of the asymmetrically dimethylated and
monomethylated arginines were found in Arg-Xaa-Arg cluster
(28).
Role of Methylation of EWS Protein—EWS protein belongs to
a large family of RNA-binding proteins that includes heteroge-
neous nuclear ribonucleoproteins, mRNA poly(A)-binding pro-
teins (32), and alternative splicing factors (33, 34). The meth-
ylation state of RNA-binding proteins (Table II) is likely to
have an important effect on their function. One type of meth-
ylated RNA binding domain consists of RGG boxes, defined as
closely repeated RGG tripeptides interrupted by other amino
acids. The RNA binding of EWS protein is localized in the
C-terminal domain, which contains RGG boxes (Ref. 10; Fig. 2,
residues 288–656). Considering the RNA binding properties of
these proteins, arginine methylation in the RNA binding do-
main may regulate the RNA-EWS protein interaction most
likely by preventing hydrogen bonding, by short range ionic
interactions, and/or by introducing steric constraints and
therefore diminishes otherwise strong interactions between
unmodified arginine residues and RNA (35). The methylated
form of one of the well studied shuttling heterogeneous nuclear
TABLE II
Comparison of the mapped sites of asymmetric dimethylation of EWS protein and other recently reported proteins with the
















EWS protein (29 sites) 45/3a 52b 38c 100 100 72d 14/14e
Review (20 sites) (from Ref. 22) 35/35 75 80 100 100 75 35/30
hnRNP A1 (3 sites) (from Ref. 29) 33/33 33 100 100 100 100 33/33
High molecular weight fibroblast growth
factor-2 (8 sites) (from Ref. 30)
50/0 38 88 100 88 0 50/0
Total (60 sites) 42/15 57 61 100 98 65 27/18
a–e Other amino acid residues found in these positions (%): a Asp, 3; Leu, 3; Met, 3; Asn, 7; Pro, 7; Arg, 28; b Asp, 3; Glu, 3; Phe, 3; Met, 14; Pro,
7; Arg, 10; Ser, 3; c Asp, 21; Phe, 7; Leu, 3; Met, 7; Asn, 3; Pro, 7; Arg, 7; Ser, 7; d Met, 7; Asn, 3; Pro, 3; Arg, 10; Ser, 3; e Asp, 10; Leu, 7; Met, 7;
Pro, 24; Arg, 24.
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ribonucleoproteins, A1, showed decreased affinity for single-
stranded DNA compared with the unmethylated form (36).
The changes in the physico-chemical properties, e.g. in-
creased hydrophobicity, loss of hydrogen bonding, and ionic
interactions resulting from arginine methylation of nuclear as
well as of cell-surface-localized EWS protein, might favor cross-
ing the various cellular membranes or its embedding in the
plasma membrane. Arginine methylation was found to facili-
tate export of certain heterogeneous nuclear ribonucleoproteins
out of the nucleus, especially of proteins that bind mRNA (37).
These observations suggest that methylation of EWS protein
may play a role in its nucleocytoplasmic shuttling and that it
acts as a carrier for export of RNA constituents to the cytosol
due to its RNA binding properties.
Asymmetric methylation might also play a role in signal
transduction. Stimulation of pre-B cells with lipopolysaccha-
ride resulted in increased methylation of membrane proteins
(22). EWS protein, which is as the present results show exten-
sively methylated on arginine residues, was found to interact
with cellular kinases, suggesting its participation in cell sig-
naling and proliferation. Under conditions leading to Bruton’s
tyrosine kinase activation, EWS protein was phosphorylated on
tyrosines in mitotically arrested B cells (13) and interacted
with Pyk2 in an activation-dependent manner (14).
The presence of asymmetrically arginine-dimethylated EWS
protein as well as of nucleolin on the cell surface raises the
question as to the significance of this localization. The present
findings, i.e. the shuttling properties, together with the dis-
cussed properties of the EWS protein allow one to speculate
that EWS protein or putative splicing products thereof can
function as binding proteins or receptors for various ligands on
the cell surface, e.g. nucleic acids, be it alone or in a complex
with other proteins and, thus, might mediate, in an alternative
regulation mechanism, between extracellular and nuclear
events.
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